Peter C. Scacheri

Peter C. Scacheri

Auto-generated profile, based on publicly available information

Peter C. Scacheri

Department of Genetics and Genome Sciences, Case Western Reserve University

Research Focus & Metrics

Academic Career Length

19Years (2008-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Genome Research
Verified
Journal Article
Closed access
PDF file
GZGabriel Zentner
Gabriel Zentner
PTPaul J. Tesar
Paul J. Tesar
PSPeter C. Scacheri
Peter C. Scacheri
Epigenetic regulation of gene enhancer elements is important for establishing and maintaining the identity of cells. Gene enhancer elements are thought to exist in either active or poised states distinguishable by chromatin features, but a complete understanding of the regulation of enhancers is lacking. Here, by using mouse embryonic stem cells and their differentiated derivatives, as well as terminally differentiated cells, we report the coexistence of multiple, defined classes of enhancers that serve distinct cellular functions. Specifically, we found that active enhancers can be subclassified based on varying levels of H3K4me1, H3K27ac, and H3K36me3 and the pSer2/5 forms of RNA polymerase II. The abundance of these histone modifications positively correlates with the expression of associated genes and cellular functions consistent with the identity of the cell type. Poised enhancers can also be subclassified based on presence or absence of H3K27me3 and H3K9me3, conservation, genomic location, expression levels of associated genes, and predicted function of associated genes. These findings not only refine the repertoire of histone modifications at both active and poised gene enhancer elements but also raise the possibility that enhancers associated with distinct cellular functions are partitioned based on specific combinations of histone modifications.

6 November 2013 in Genome Research
Verified
Journal Article
Open access
PDF file
OCOlivia Corradin
Olivia Corradin
ASAlina Saiakhova
Alina Saiakhova
BABatool Akhtar-Zaidi
Batool Akhtar-Zaidi
LMLois Myeroff
Lois Myeroff
JWJoseph Willis
Joseph Willis
PSPeter C. Scacheri
Peter C. Scacheri
DNA variants (SNPs) that predispose to common traits often localize within noncoding regulatory elements such as enhancers. Moreover, loci identified by genome-wide association studies (GWAS) often contain multiple SNPs in linkage disequilibrium (LD), any of which may be causal. Thus, determining the effect of these multiple variant SNPs on target transcript levels has been a major challenge. Here, we provide evidence that for six common autoimmune disorders (rheumatoid arthritis, Crohn's disease, celiac disease, multiple sclerosis, lupus, and ulcerative colitis), the GWAS association arises from multiple polymorphisms in LD that map to clusters of enhancer elements active in the same cell type. This finding suggests a “multiple enhancer variant” hypothesis for common traits, where several variants in LD impact multiple enhancers and cooperatively affect gene expression. Using a novel method to delineate enhancer–gene interactions, we show that multiple enhancer variants within a given locus typically target the same gene. Using available data from HapMap and B lymphoblasts as a model system, we provide evidence at numerous loci that multiple enhancer variants cooperatively contribute to altered expression of their gene targets. The effects on target transcript levels tend to be modest and can be either gain- or loss-of-function. Additionally, the genes associated with multiple enhancer variants encode proteins that are often functionally related and enriched in common pathways. Overall, the multiple enhancer variant hypothesis offers a new paradigm by which noncoding variants can confer susceptibility to common traits.

21 November 2019 in Cell
Verified
Journal Article
Closed access
AMAndrew R. Morton
Andrew R. Morton
NDNergiz Dogan-Artun
Nergiz Dogan-Artun
ZFZachary J. Faber
Zachary J. Faber
GMGraham MacLeod
Graham MacLeod
CBCynthia F. Bartels
Cynthia F. Bartels
PSPeter C. Scacheri
Peter C. Scacheri

22 February 2010 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
GZGabriel Zentner
Gabriel Zentner
WLWanda S. Layman
Wanda S. Layman
DMDonna Martin
Donna Martin
PSPeter C. Scacheri
Peter C. Scacheri

11 May 2012 in Science
Verified
Journal Article
Closed access
PDF file
BABatool Akhtar-Zaidi
Batool Akhtar-Zaidi
RCRichard Cowper-Sal·lAri
Richard Cowper-Sal·lAri
OCOlivia Corradin
Olivia Corradin
ASAlina Saiakhova
Alina Saiakhova
CBCynthia F. Bartels
Cynthia F. Bartels
PSPeter C. Scacheri
Peter C. Scacheri
Colorectal Cancer Signature: The mutations and genome aberrations that characterize cancer result in often dramatically altered gene and protein expression patterns. It is these altered expression patterns that directly and indirectly drive progression of the disease. In human primary colorectal cancer cells, Akhtar-Zaidi et al. (p. 736 , published online 12 April) analyzed the pattern of epigenetically modified chromatin at “enhancer” sequences that are known to be critical in the control of gene expression. An epigenetic enhancer signature was defined that was specifically associated with colorectal cancer cells.

15 July 2010 in PLOS Genetics
Verified
Journal Article
Open access
PDF file
MSMichael P. Schnetz
Michael P. Schnetz
LHLusy Handoko
Lusy Handoko
BABatool Akhtar-Zaidi
Batool Akhtar-Zaidi
CBCynthia F. Bartels
Cynthia F. Bartels
CPC. Filipe Pereira
C. Filipe Pereira
PSPeter C. Scacheri
Peter C. Scacheri
CHD7 is one of nine members of the chromodomain helicase DNA–binding domain family of ATP–dependent chromatin remodeling enzymes found in mammalian cells. De novo mutation of CHD7 is a major cause of CHARGE syndrome, a genetic condition characterized by multiple congenital anomalies. To gain insights to the function of CHD7, we used the technique of chromatin immunoprecipitation followed by massively parallel DNA sequencing (ChIP–Seq) to map CHD7 sites in mouse ES cells. We identified 10,483 sites on chromatin bound by CHD7 at high confidence. Most of the CHD7 sites show features of gene enhancer elements. Specifically, CHD7 sites are predominantly located distal to transcription start sites, contain high levels of H3K4 mono-methylation, found within open chromatin that is hypersensitive to DNase I digestion, and correlate with ES cell-specific gene expression. Moreover, CHD7 co-localizes with P300, a known enhancer-binding protein and strong predictor of enhancer activity. Correlations with 18 other factors mapped by ChIP–seq in mouse ES cells indicate that CHD7 also co-localizes with ES cell master regulators OCT4, SOX2, and NANOG. Correlations between CHD7 sites and global gene expression profiles obtained from Chd7+/+, Chd7+/−, and Chd7−/− ES cells indicate that CHD7 functions at enhancers as a transcriptional rheostat to modulate, or fine-tune the expression levels of ES–specific genes. CHD7 can modulate genes in either the positive or negative direction, although negative regulation appears to be the more direct effect of CHD7 binding. These data indicate that enhancer-binding proteins can limit gene expression and are not necessarily co-activators. Although ES cells are not likely to be affected in CHARGE syndrome, we propose that enhancer-mediated gene dysregulation contributes to disease pathogenesis and that the critical CHD7 target genes may be subject to positive or negative regulation. The gene encoding chromodomain helicase DNA–binding protein 7 (CHD7) is required for normal mammalian development. In humans, genetic mutations in CHD7 lead to CHARGE syndrome, a disorder characterized by multiple birth defects. In previous studies, CHD7 was shown to localize to the cell nucleus and bind to specific sites on chromatin. However, the genome-wide distribution of CHD7 on chromatin and its function are not known. Here, we identified 10,483 sites on chromatin bound by CHD7 in mouse embryonic stem cells. Many of these sites are gene enhancer elements suspected to be involved in turning on genes. We show CHD7 functions at these loci to fine-tune the levels of genes that are specifically expressed in mouse ES cells. This modulation is mediated through several proteins that bind together with CHD7 at enhancer elements and can occur in either direction. These findings suggest CHARGE syndrome is the result of key genes that are improperly expressed during development. These key genes are currently unknown but are likely to be tissue-specific and may be upregulated or downregulated in response to CHD7 mutation.